Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Case-control study to evaluate the Large local reactions following a change in the vaccination schedule of hexavalent DTaP-IPV-Hib-HB (Infanrix-hexa) and quadrivalent measles-mumps-rubella-varicella vaccine (MMRV, ProQuad) in children at 18 months of age

Trial Profile

A Case-control study to evaluate the Large local reactions following a change in the vaccination schedule of hexavalent DTaP-IPV-Hib-HB (Infanrix-hexa) and quadrivalent measles-mumps-rubella-varicella vaccine (MMRV, ProQuad) in children at 18 months of age

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2018

At a glance

  • Drugs Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa) (Primary) ; MMR-varicella zoster virus vaccine (Primary)
  • Indications Chickenpox; Diphtheria; Haemophilus infections; Hepatitis B; Measles; Mumps; Pertussis; Poliomyelitis; Rubella; Tetanus
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Oct 2018 New trial record
    • 27 Sep 2018 Results published in the Vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top